Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052027 | 1.00 | SLC7A5 (0.38) | SLC7A5 | |
| SCHEMBL150490 | 1.00 | SLC7A5 (0.38) | SLC7A5 | |
| Hydrochloric Acid SCHEMBL9789200 | 0.98 | SLC7A5 (0.36) | SLC7A5 | |
| SCHEMBL2513127 | 0.89 | SLC7A5 (0.30) | SLC7A5 | |
| SCHEMBL9489841 | 0.82 | — | — | |
| SCHEMBL27765896 | 0.82 | CPB2 (0.31) | — | |
| SCHEMBL9789201 | 0.82 | — | — | |
| SCHEMBL679593 | 0.81 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL5283576 | 0.81 | SLC7A5 (0.33) | SLC7A5 | |
| Hydrochloric Acid SCHEMBL9789372 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0338939-B1 | HISTAMINE DERIVATIVE, PROCESS FOR HIS PREPARATION AND HIS THERAPEUTIC APPLICATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-01-27 | — | — | EP | claimed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | claimed |
| US-20210244796-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHOIPHILIC COMPOUNDS CONTAINING HYDRIPHOBIC RADICALS | ADOCIA (FR) | 2021-08-12 | — | — | US | disclosed |
| EP-3829624-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHIPHILIC COMPOUND CONTAINING HYDROPHOBIC RADICALS | Adocia (FR) | 2021-06-09 | — | — | EP | disclosed |
| CN-112805025-A | Injectable aqueous composition comprising an amylin, an amylin receptor agonist or an amylin analog, at least one ionic substance and an amphiphilic compound comprising a hydrophobic group | 阿道恰公司 | 2021-05-14 | — | — | CN | disclosed |
| WO-2020025825-A1 | INJECTABLE SOLUTION HAVING PH 7 AND COMPRISING HUMAN GLUCAGON, AT LEAST ONE IONIC SPECIES, AND AN AMPHIPHILIC COMPOUND BEARING HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020025826-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHIPHILIC COMPOUND CONTAINING HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020025824-A1 | INJECTABLE SOLUTION AT PH 7, COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5, AT LEAST ONE IONIC SPECIES, AND AN AMPHIPHILIC COMPOUND BEARING HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-02-06 | — | — | WO | disclosed |
| CN-101778857-A | Platinum (IV) complex compound | PLATCO TECHNOLOGIES PROPRIETAR | 2010-07-14 | — | — | CN | disclosed |
| EP-0338939-B1 | HISTAMINE DERIVATIVE, PROCESS FOR HIS PREPARATION AND HIS THERAPEUTIC APPLICATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-01-27 | — | — | EP | disclosed |
| EP-0523087-A1 | HIGH IMPACT POLYETHYLENE TEREPHTHALATE-POLYCARBONATE BLEND COMPOSITIONS | AlliedSignal Inc. (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5034539-A | Histamine derivative, process for preparing it and its therapeutic use | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1991-07-23 | — | — | US | disclosed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244796-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHOIPHILIC COMPOUNDS CONTAINING HYDRIPHOBIC RADICALS | GLP1R, IAPP, GPR119 | SLC7A5 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.